( G10 is currently being studied inclini...)Positive results from placebo-controlled phase IIa study in,patients suffering from house dust mite allergy,Health

G10 is currently being studied in clinical trials for the treatment of
allergic rhinitis and atopic dermatitis.

About allergic diseases
Allergy as a whole is a multi-faceted disease and clinically manifests in various allergic disorders
including allergic rhinitis, asthma, atopic dermatitis and food hypersensitivity. It is an exaggerated
reaction by the patient’s immune system to a normally harmless substance such as various
environmental proteins present in pollen, dust mite faeces, or food. According to the World Health
Organization, more than 20% of the world population suffers from allergic diseases (WHO, 2002).
Allergy to house dust mites is one of the most common causes of allergic disease worldwide and it is
estimated that nearly 50% of allergic people are sensitized to dust mite allergens (Clin Exp Allergy,
2004;34:597). Dust mite allergy frequently starts with symptoms of rhinitis, but over the longer term
many patients may develop symptoms of asthma. Today, three general approaches are commonly
being pursued to relieve the symptoms of allergic diseases: avoidance of the allergen, prescription of
medication that targets disease symptoms, and conventional immunotherapy, also known as
desensitization. The latter is the only disease-modifying treatment available, however, it is timeconsuming
(3-5 years) and inconvenient for the patients. Therefore, a significant unmet medical
need remains for allergic disease treatment.


For further information please contact:
Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren
Claudine Blaser, PhD
Director Corporate Communications
Tel.: +41 44 733 47 20
e-Mail: claudine.blaser@cytos.com
Webseite: www.cytos.com

About Cytos Biotechno
'"/>




Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis